Free Trial

Extendicare Inc. (TSE:EXE) Receives Average Rating of "Moderate Buy" from Analysts

Extendicare logo with Medical background

Key Points

  • Extendicare Inc. has received a consensus rating of "Moderate Buy" from analysts, with three holding, two buying, and two giving a strong buy rating.
  • The average 1-year target price for Extendicare's stock among analysts is C$15.20, with National Bankshares increasing their target from C$16.10 to C$17.50.
  • Extendicare announced a monthly dividend of $0.042 per share, which gives an annual yield of 3.1%, with the ex-dividend date set for October 31st.
  • MarketBeat previews the top five stocks to own by November 1st.

Shares of Extendicare Inc. (TSE:EXE - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is C$15.20.

EXE has been the topic of several recent research reports. National Bankshares increased their price target on Extendicare from C$16.10 to C$17.50 and gave the company an "outperform" rating in a report on Wednesday, October 8th. CIBC set a C$18.00 target price on Extendicare and gave the stock an "outperform" rating in a research note on Monday, September 22nd. National Bank Financial upgraded Extendicare to a "strong-buy" rating in a research note on Wednesday, July 16th. Finally, Cibc World Mkts upgraded Extendicare to a "strong-buy" rating in a research note on Monday, September 22nd.

View Our Latest Stock Report on Extendicare

Extendicare Trading Up 0.9%

Shares of EXE stock opened at C$16.22 on Friday. The firm has a fifty day moving average price of C$14.07 and a 200-day moving average price of C$13.79. Extendicare has a 1 year low of C$8.96 and a 1 year high of C$16.39. The company has a debt-to-equity ratio of 283.02, a current ratio of 0.62 and a quick ratio of 0.98. The company has a market cap of C$1.36 billion, a price-to-earnings ratio of 16.81 and a beta of 0.88.

Extendicare Dividend Announcement

The firm also recently declared a monthly dividend, which will be paid on Monday, November 17th. Shareholders of record on Monday, November 17th will be issued a $0.042 dividend. This represents a c) annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, October 31st. Extendicare's dividend payout ratio (DPR) is currently 50.57%.

About Extendicare

(Get Free Report)

Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.

Featured Articles

Analyst Recommendations for Extendicare (TSE:EXE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Extendicare Right Now?

Before you consider Extendicare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.

While Extendicare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.